The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Allosteric Small Molecule Therapies for Treating GBA1-PD
Study Rationale: Some people with Parkinson’s disease (PD) have a change, or mutation, in a gene called GBA1. This gene makes an important enzyme called GCase, which helps keep brain cells healthy...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Lead Optimization of a B1-selective AMPK-activator for Treatment of PD
Study Rationale: Overwhelming evidence indicates that mitochondrial dysfunction contributes to the development of Parkinson’s disease (PD). We have shown that activating the enzyme AMPK prevents...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Isoform Specific Suppression of dIRE-SNCA with an ASO
Study Rationale: Alpha-synuclein (SNCA) aggregation is a hallmark of Parkinson’s disease (PD). Rare SNCA genetic duplications and triplications cause early-onset PD, suggesting a link between SNCA...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Next Generation Treg Therapy for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) occurs because of the degeneration of the neurons that produce the neurotransmitter dopamine. This causes the disease signs and symptoms. Nerve cell...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Novel Small Molecules to Slow PD Progression in a Genetically Defined Subset of People with PD
Study Rationale: Currently, drug discovery efforts for neurodegeneration are almost exclusively focused on disease risk, not the progression biology that afflicts patients when they present with...
-
Research Grant, 2025Characterization of Research Antibodies for Parkinson’s Community-nominated Targets
Study Rationale: Antibodies are essential for detecting proteins, but nearly 50% of commercial antibodies fail to work reliably—like a GPS that’s only right half the time. In Parkinson’s research...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.